FDA approves new cancer drug while early-onset diabetes surges in young women; healthcare systems grapple with ED boarding crisis and heat-related mortality spikes in Europe

The FDA approved a new ROS1 inhibitor for non-small cell lung cancer (NSCLC) patients who previously received another drug from the same class, expanding treatment options for this patient population.

Data spanning 13 years reveals a concerning trend: early-onset diabetes incidence is climbing among adults under 40 years old, while rates are falling in older age groups, with young women driving much of this rise.

The MHRA contraindicated domperidone use in phaeochromocytoma patients following a European safety review that identified four reports of severe hypertension linked to the medication in these individuals.

Emergency departments nationwide are facing a worsening boarding crisis, with patients increasingly waiting for hours or even days in hallways, becoming a systemic challenge in hospital operations.

Early real-world data show encouraging results for at-home subcutaneous lecanemab administered weekly, suggesting it may serve as a feasible alternative to ongoing intravenous maintenance treatment for early Alzheimer's disease.

Adult-gerontology nurse practitioners are emerging as a potential solution to elder care demands, with growing opportunities in this specialized nursing field as the aging population increases.

France recorded 5,764 excess deaths between June 17 and July 2 during severe heatwaves, highlighting the significant public health impact of extreme heat events on mortality rates.

Nearly one-third of US adults report intentional outdoor tanning in a national survey, a widespread practice that increases sunburn risk and raises concerns about skin cancer prevention.